人乳头瘤病毒疫苗接种预防感染及相关癌症的研究进展

doi:10.19871/j.cnki.xfcrbzz.2023.06.016

摘要/Abstract

摘要： 人乳头瘤病毒（human papilloma virus,HPV）持续感染是HPV相关性癌症如宫颈癌、阴道癌、外阴癌、肛门癌、阴茎癌以及口咽癌等的主要致病因素,接种HPV疫苗可预防HPV感染和相关性癌症的发生,是防控HPV感染相关疾病的一级预防措施。HPV疫苗是全球第一个用于预防癌症的疫苗,自应用于临床以来,HPV感染率及其相关宫颈癌的发病率有所下降,疫苗展示出良好的保护效力和安全性,同时也积累了一些关于口腔、外阴和阴道、阴茎和肛门部位HPV感染和相关癌症的研究数据。伴随着接种范围的增加及适应证的扩大,HPV疫苗的安全性也受到越来越多的关注。本文根据最新文献综述HPV疫苗的保护效果及安全性的研究进展,为HPV疫苗的接种提供数据参考。

关键词: 人乳头瘤病毒, 疫苗, 感染, 癌症, 有效性

Abstract: Persistent infection with human papilloma virus (HPV) is a major cause of HPV-related cancers such as cervical, vaginal and vulvar cancers, as well as anal, penile and oropharyngeal cancers.HPV vaccination can prevent the occurrence of HPV infection and related cancers, and is a primary prevention measure for the prevention and control of HPV infection-related diseases HPV vaccine is the world's first vaccine for cancer prevention, since the clinical application, the incidence of HPV infection and its associated cervical cancer has decreased, the vaccine has shown good protective efficacy and safety, but also accumulated some research data on oral, vulvar and vagina, penis and anal HPV infection and related cancers. With the increase in the scope of vaccination and the expansion of indications, the safety of HPV vaccines has also received more and more attention. This article reviews the research progress on the protective effect and safety of HPV vaccine according to the latest literature, and provides data reference for HPV vaccine vaccination.

Key words: Human papilloma virus, Vaccine, Infection, Cancer, Effectiveness

中图分类号:

R186

张莹, 曾妍茗, 鲁雁秋, 陈耀凯. 人乳头瘤病毒疫苗接种预防感染及相关癌症的研究进展[J]. 新发传染病电子杂志, 2023, 8(6): 84-88.

Zhang Ying, Zeng Yanming, Lu Yanqiu, Chen Yaokai. The progress of human papilloma virus vaccination to prevent infection and related cancers[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(6): 84-88.

参考文献

[1] ALHAMLAN FS, ALFAGEEH MB, AL MUSHAIT MA, et al.Human Papilloma virus- Associated Cancers[J]. Adv Exp Med Biol, 2021, 1313: 1-14.
[2] DING W, MA Y, MA C, et al.The Lifetime Cost Estimation of Human Papilloma virus-related Diseases in China: A Modeling Study[J]. J Transl Int Med, 2021, 9(3): 200-211.
[3] DE SANJOSÉ S, SERRANO B, TOUS S, et al. Burden of Human Papilloma virus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58[J]. JNCI Cancer Spectr, 2018, 2(4): pky045.
[4] MANINI I, MONTOMOLI E.Epidemiology and prevention of Human Papilloma virus[J]. Ann Ig, 2018, 30(4 Supple 1): 28-32.
[5] SHEN Y, XIA J, LI H, et al.Human papilloma virus infection rate, distribution characteristics, and risk of age in pre- and postmenopausal women[J]. BMC Womens Health, 2021, 21(1): 80.
[6] SUNG H, FERLAY J, SIEGEL RL, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021,71(3): 209-249.
[7] WEI L, XIE X, LIU J, et al.Efficacy of quadrivalent human papilloma virus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up[J]. Vaccine, 2019, 37(27): 3617-3624.
[8] JOURA EA, GIULIANO AR, IVERSEN OE, et al.A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women[J]. N Engl J Med, 2015, 372(8): 711-23.
[9] LUOSTARINEN T, APTER D, DILLNER J, et al.Vaccination protects against invasive HPV-associated cancers[J]. Int J Cancer, 2018, 142(10): 2186-2187.
[10] STEBEN M, TAN THOMPSON M, RODIER C, et al.A Review of the Impact and Effectiveness of the Quadrivalent Human Papilloma virus Vaccine: 10 Years of Clinical Experience in Canada[J]. J Obstet Gynaecol Can, 2018, 40(12): 1635-1645.
[11] LEI J, PLONER A, ELFSTRÖM KM, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer[J]. N Engl J Med, 2020, 383(14): 1340-1348.
[12] GARLAND SM, JOURA EA, AULT KA, et al.Human Papilloma virus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age[J]. Obstet Gynecol, 2018, 132(2): 261-270.
[13] XU L, SELK A, GARLAND SM, et al.Prophylactic vaccination against human papilloma viruses to prevent vulval and vaginal cancer and their precursors[J]. Expert Rev Vaccines, 2019, 18(11): 1157-1166.
[14] DEHLENDORFF C, BAANDRUP L, KJAER SK.Real-World Effectiveness of Human Papilloma virus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers[J]. J Natl Cancer Inst, 2021, 13(7): 869-874.
[15] MIX JM, SARAIYA M, SENKOMAGO V, et al.High-Grade Vulvar, Vaginal, and Anal Precancers Among U.S. Adolescents and Young Adults After Human Papilloma virus Vaccine Introduction[J]. Am J Prev Med, 2022, 62(1): 95-99.
[16] BECHINI A, MOSCADELLI A, VELPINI B, et al.Efficacy of HPV Vaccination Regarding Vulvar and Vaginal Recurrences in Previously Treated Women: The Need for Further Evidence[J]. Vaccines (Basel), 2023, 11(6): 1084.
[17] ALENE T, ATNAFU A, MEKONNEN ZA, et al.Acceptance of Human Papilloma virus Vaccination and Associated Factors Among Parents of Daughters in Gondar Town, Northwest Ethiopia[J]. Cancer Manag Res, 2020, 12: 8519-8526.
[18] GIULIANO AR, JOURA EA, GARLAND SM, et al.Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population[J]. Gynecol Oncol, 2019, 154(1): 110-117.
[19] BERTOLI HK, BAANDRUP L, AALBORG GL, et al.Time trends in the incidence and survival of vaginal squamous cell carcinoma and high-grade vaginal intraepithelial neoplasia in Denmark - A nationwide population-based study[J]. Gynecol Oncol, 2020, 158(3): 734-739.
[20] SAUNDERS CL, MEADS C, ABEL GA, et al.Associations Between Sexual Orientation and Overall and Site-Specific Diagnosis of Cancer: Evidence From Two National Patient Surveys in England[J]. J Clin Oncol, 2017,35(32):3654-3661.
[21] MEITES E, WINER RL, NEWCOMB ME, et al.Vaccine Effectiveness Against Prevalent Anal and Oral Human Papilloma virus Infection Among Men Who Have Sex With Men-United States, 2016-2018[J]. J Infect Dis, 2020, 222(12): 2052-2060.
[22] GOLDSTONE SE, GIULIANO AR, PALEFSKY JM, et al.Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial[J]. Lancet Infect Dis, 2022, 22(3): 413-425.
[23] VANTHOOR J, VOS G, ALBERSEN M.Penile cancer: potential target for immunotherapy?[J]. World J Urol, 2021,39(5): 1405-1411.
[24] STRATTON KL, CULKIN DJ.A Contemporary Review of HPV and Penile Cancer[J]. Oncology (Williston Park), 2016, 30(3): 245-249.
[25] IORGA L, DRAGOS MARCU R, CRISTINA DIACONU C, et al.Penile carcinoma and HPV infection (Review)[J]. Exp Ther Med, 2020, 20(1): 91-96.
[26] GU W, ZHANG P, ZHANG G, et al.Importance of HPV in Chinese Penile Cancer: A Contemporary Multicenter Study[J]. Front Oncol, 2020, 10:1521.
[27] GIULIANO AR, PALEFSKY JM, GOLDSTONE S, et al.Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males[J]. N Engl J Med, 2011, 364(5): 401-411.
[28] WINER RL, LIN J, QUEREC TD, et al.Effectiveness of Human Papilloma virus (HPV) Vaccination Against Penile HPV Infection in Men Who Have Sex With Men and Transgender Women[J]. J Infect Dis, 2022, 225(3): 422-430.
[29] ROMAN BR, ARAGONES A.Epidemiology and incidence of HPV-related cancers of the head and neck[J]. J Surg Oncol, 2021,124(6): 920-922.
[30] OFFICE FOR NATIONAL STATISTICS. Cancer registration statistics, England[EB/OL].(2018-01-25)[2023-09-19]. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/2016.
[31] GILLISON ML, CHATURVEDI AK, ANDERSON WF, et al.Epidemiology of Human Papilloma virus-Positive Head and Neck Squamous Cell Carcinoma[J]. J Clin Oncol, 2015, 33(29): 3235-3242.
[32] CHATURVEDI AK, GRAUBARD BI, BROUTIAN T, et al.Effect of Prophylactic Human Papilloma virus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States[J]. J Clin Oncol, 2018, 36(3): 262-267.
[33] SCHLECHT NF, MASIKA M, DIAZ A, et al.Risk of Oral Human Papilloma virus Infection Among Sexually Active Female Adolescents Receiving the Quadrivalent Vaccine[J]. JAMA Netw Open, 2019,2(10): e1914031.
[34] HERRERO R, QUINT W, HILDESHEIM A, et al.Reduced prevalence of oral human papilloma virus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica[J]. PLoS One, 2013,8(7):e68329.
[35] KACZMARCZYK KH, YUSUF H.The impact of HPV vaccination on the prevention of oropharyngeal cancer: A scoping review[J]. Community Dent Health. 2022, 39(1): 14-21.
[36] DAMGACIOGLU H, SONAWANE K, CHHATWAL J, et al.Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling study[J]. Lancet Reg Health Am, 2022, 8: 100143.
[37] 李双, 孔北华. 人乳头瘤病毒疫苗临床应用中国专家共识(2021年版)解读[J]. 实用妇产科杂志, 2022,38(11): 827-831.
[38] 陈汶, 赵昀, 谢幸, 等. 四价人乳头瘤病毒疫苗在中国大陆女性中的安全性:一项随访90个月的随机、双盲、安慰剂对照研究[J]. 中国妇产科临床杂志, 2020, 21(6): 585-588.
[39] YAN X, LI H, SONG B, et al.Association of periconceptional or pregnancy exposure of HPV vaccination and adverse pregnancy outcomes: a systematic review and meta-analysis with trial sequential analysis[J]. Front Pharmacol, 2023, 14: 1181919.
[40] BONANNI P, ZANELLA B, SANTOMAURO F, et al.Safety and perception: What are the greatest enemies of HPV vaccination programmes[J]. Vaccine, 2018, 36(36): 5424-5429.